LXEO (Lexeo Therapeutics) Accounts Payable: $3.34 Mil (As of Mar. 2026)


LXEO Lexeo Therapeutics Inc LXEO
10 GF Score
Price $4.81
! 3 Warning Signs
View Full Analysis

What is Lexeo Therapeutics Accounts Payable?

Lexeo Therapeutics LXEO -4.55% 10 Accounts Payable is $3.34 Mil as of Mar. 2026. GuruFocus rates LXEO with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

Lexeo Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $3.34 Mil.

Lexeo Therapeutics's quarterly Accounts Payable increased from Sep. 2025 ($4.66 Mil) to Dec. 2025 ($4.86 Mil) but then declined from Dec. 2025 ($4.86 Mil) to Mar. 2026 ($3.34 Mil).

Lexeo Therapeutics's annual Accounts Payable increased from Dec. 2023 ($3.79 Mil) to Dec. 2024 ($6.42 Mil) but then declined from Dec. 2024 ($6.42 Mil) to Dec. 2025 ($4.86 Mil).

Lexeo Therapeutics Accounts Payable Related Terms

Lexeo Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Lexeo Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexeo Therapeutics Accounts Payable Chart

Lexeo Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 3.06 2.68 3.79 6.42 4.86

Lexeo Therapeutics Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.98 20.03 4.66 4.86 3.34
LXEO
10GF Score
Lexeo Therapeutics Inc LXEO
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexeo Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $3.34 Mil mean?
Lexeo Therapeutics (LXEO) has a Accounts Payable of $3.34 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lexeo Therapeutics and its competitors.
Is Lexeo Therapeutics' Accounts Payable too high?
Lexeo Therapeutics' current Accounts Payable is $3.34 Mil. Overall, Lexeo Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Lexeo Therapeutics' Accounts Payable compare to PROK and CMPX?
Lexeo Therapeutics' Accounts Payable of $3.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lexeo Therapeutics and its competitors. Lexeo Therapeutics's current Accounts Payable is $3.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexeo Therapeutics stock overvalued right now?
Lexeo Therapeutics (LXEO) has a current Accounts Payable of $3.34 Mil. The current Accounts Payable is $3.34 Mil. Lexeo Therapeutics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Lexeo Therapeutics (LXEO), the current Accounts Payable is $3.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lexeo Therapeutics Business Description

Address 345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
10GF Score

Get the complete analysis for LXEO

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.81
Price